sf-837 and Respiratory-Tract-Infections

Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Humans; Leucomycins; Pneumonia, Bacterial; Respiratory Tract Infections

Topics: Adult; Anti-Bacterial Agents; Exanthema; Female; Humans; Leucomycins; Respiratory Tract Infections; Skin; Skin Tests

Planned study of 110 patients suffering infections of the upper respiratory tract. Soon after a smear of the focus for bacterial examination was taken a treatment with diacetyl-midecamycin was scheduled during 7 days. Thereafter another control smear and checking of the clinical status was realized. The issue of the study was very good, excepting 3 cases in which the drug was discontinued owing to gastrointestinal intolerance.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; Clinical Protocols; Female; Humans; Leucomycins; Male; Middle Aged; Respiratory Tract Infections

Clinical trials of 9,3"-diacetylmidecamycin (MOM), a new macrolide antibiotic were carried out on 46 pediatric patients of 1 month to 11 years old with infections (acute pharyngitis 12, acute tonsillitis 1, acute bronchitis 14, asthmatic bronchitis 10, acute pneumonia 1, primary atypical pneumonia 2, Mycoplasma pneumonia 4 and pertussis 2). As a rule, MOM was given orally at a daily dose of 20 approximately 40 mg/kg divided into 3 times. The clinical results were excellent in 5 patients, good in 21, fair in 7 and poor in 13 and the efficacy rate was 56.5%. Side effects were observed in 4 patients (diarrhea, exanthema, urticaria and eosinophilia, 1 patient respectively). MOM is easy to take and a useful antibiotic for treating patients with bacterial infections, in particular, respiratory tract infection caused by Mycoplasma pneumoniae.

Topics: Administration, Oral; Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Leucomycins; Male; Miocamycin; Pneumonia, Mycoplasma; Respiratory Tract Infections

1. The dry syrup of MOM was administered orally to 17 patients mainly with heart diseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases, the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20 mg/kg treatment. The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was 60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3 cases. 7. Any pediatric patient did not refuse taking.

Topics: Administration, Oral; Age Factors; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; Female; Humans; Leucomycins; Male; Miocamycin; Respiratory Tract Infections